IP Library Granted Patent US 8,470,977
Granted Patent B2
US 8,470,977 · App. 13/026,944 · Granted Jun 25, 2013

Antibody against the CSF-1R

Inventors: Hélène Haegel (Illkirch-Graffenstaden, FR); Christine Thioudellet (Strasbourg, FR); Michel Geist (Brumath, FR); Benoît Grellier (Strasbourg, FR); Jean-Baptiste Marchand (Obernai, FR)
Assignee: Transgene S.A.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,470,977
App. No.
13/026,944
Granted
Jun 25, 2013
Kind
B2
Abstract

The present invention provides antibodies specific for the CSF-1R, compositions comprising said antibodies and methods of treatment using such compositions.

Claims (11)

1. An isolated, recombinant, or purified antibody that specifically binds to human CSF-1R, comprising a heavy chain and a light chain, wherein the heavy chain comprises SEQ ID NO:37 or SEQ ID NO:38, and the light chain comprises SEQ ID NO:39, SEQ ID NO:40, or SEQ ID NO:41.

2. An isolated, recombinant, or purified antibody that specifically binds to human CSF-1R, comprising:

(a) a heavy chain comprising a first variable region, and

(b) a light chain comprising a second variable region;

wherein the first variable region comprises SEQ ID NO:42 or SEQ ID NO:43, and the second variable region comprises SEQ ID NO:44, SEQ ID NO:45, or SEQ ID NO:46.

3. The antibody of claim 1 , wherein the heavy chain comprises SEQ ID NO:37, and the light chain comprises SEQ ID NO:39.

4. The antibody of claim 1 , wherein the heavy chain comprises SEQ ID NO:38, and the light chain comprises SEQ ID NO:40.

5. The antibody of claim 1 , wherein the heavy chain comprises SEQ ID NO:37, and the light chain comprises SEQ ID NO:41.

6. The antibody of claim 2 , wherein the first variable region comprises SEQ ID NO:42, and the second variable region comprises SEQ ID NO:44.

7. The antibody of claim 2 , wherein the first variable region comprises SEQ ID NO:43, and the second variable region comprises SEQ ID NO:45.

8. The antibody of claim 2 , wherein the first variable region comprises SEQ ID NO:42, and the second variable region comprises SEQ ID NO:46.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 1, 2011
From: HAEGEL, HELENE; THIOUDELLET, CHRISTINE; GEIST, MICHEL; GRELLIER, BENOIT; MARCHAND, JEAN-BAPTISTE
To: TRANSGENE S.A.
Reel/Frame 026064/0106 →
Priority Claims (1)
EP 08360005 · Mar 14, 2008 · regional
Continuity (3)
Continuation In Part 12922441
Provisional Application 61043884 · Apr 10, 2008
Related Publication 20110178278A1 · Jul 21, 2011